A small slice of older breast cancer patients now have an FDA-cleared way to skip the operating room and still treat their tumors, and it literally involves putting the cancer on ice.
The Food and Drug Administration has cleared a non-surgical option for a narrow group of patients: cryoablation that freezes and destroys small tumors in women 70 and older with biologically low-risk cancers. Supporters say the approach can spare patients a trip to the hospital, a surgical scar and weeks of recovery. Skeptics point out that long-term, head-to-head data against lumpectomy are still not in, so the story is very much unfolding. The new clearance opens the door to an office-based procedure, but it arrives with tight eligibility rules and a formal requirement to track outcomes after the technology hits the market.
What The FDA Cleared
The agency granted De Novo marketing authorization on Oct. 3, 2025, for the ProSense cryoablation system, a device designed to freeze breast tumors from the inside out. The green light is narrowly limited to women aged 70 and older who have biologically low-risk, unifocal invasive ductal carcinomas no larger than 1.5 cm and who will also receive adjuvant endocrine therapy, according to the FDA.
In its own announcement, IceCure Medical said the authorization extends to some patients who are not candidates for surgery at all. The De Novo decision allows immediate marketing to that tightly defined population, while also imposing special controls so regulators can keep an eye on real-world performance.
What The Studies Show
To back up the decision, regulators leaned on the multicenter ICE3 trial, a single-arm study that followed a carefully selected group of patients treated with cryoablation plus, in most cases, endocrine therapy. Five-year results, published in Annals of Surgical Oncology, reported an ipsilateral breast tumor recurrence rate of 4.3 percent and breast-cancer-specific survival of about 96.7 percent among 194 eligible patients.
The publication spells out the enrollment criteria and the single-arm design, and it also underscores what is missing: definitive comparative data against surgery. Even supporters acknowledge that longer follow-up and direct comparisons to lumpectomy will be needed before anyone can declare cryoablation the new standard.
Surgeons' Guidance And Caveats
The American Society of Breast Surgeons has now updated its resource guide with extremely specific rules on who should even be considered for this approach. According to the ASBrS, eligible tumors should be estrogen receptor positive, progesterone receptor positive and HER2 negative, low histologic grade, ultrasound-visible, unifocal, and paired with a clinically node-negative axilla.
The group also flags some very practical headaches that have not been fully ironed out, including how follow-up imaging should be standardized and what level of operator experience should be required. Its guidance stresses that cryoablation ought to be used only as part of a multidisciplinary treatment plan and performed by clinicians who are already comfortable with ultrasound-guided interventions. In other words, this is not a do-it-yourself shortcut to avoid involving a full breast cancer team.
FDA Oversight And The Post-market Study
As a condition of marketing, the FDA is not simply trusting early data and walking away. The agency required a post-market surveillance study, and IceCure has said regulators cleared the design of the so-called ChoICE trial in March 2026, with plans to enroll roughly 400 patients at about 30 sites across the United States.
A filing with the SEC notes that participating centers may offer commercial cryoablation procedures alongside the study and that the study procedures can be billed using an established CPT Category III facility-fee code. That is a reminder that, from the outset, this technology is being watched through both a clinical and an economic lens.
Patient Trade-offs And Lingering Questions
For the women who qualify, ICE3 participants and early adopters describe a very different experience from standard surgery: an office-based procedure lasting about 30 to 45 minutes, done under local anesthesia, with minimal scarring and a comparatively fast recovery. Interventional News has featured accounts from patients and investigators describing the appeal of a quick, needle-based treatment that avoids an operating room.
At the same time, coverage by CBS News and by surgical societies has highlighted a key concern: no one can yet say with absolute confidence that freezing a tumor in place offers the same long-term local control as cutting it out. The trade-off is straightforward but serious. Patients may be able to avoid surgery, a scar and a tougher recovery, but they are also stepping into a field where the longest and most rigorous comparisons are still in progress.
Who This Is For And What Comes Next
The fine print is crucial. Because of how tightly the FDA authorization is written, most people with breast cancer will not be eligible for this option. Patients with lobular histology, multifocal disease or node-positive cancers are excluded, and higher-grade tumors do not qualify. Both the ASBrS guide and the Annals of Surgical Oncology publication on ICE3 outline those exclusions clearly.
Whether this approach will move beyond a niche option depends on what the ChoICE trial shows, how quickly clinicians can be trained and how payers decide to handle reimbursement once the post-market study is finished. For now, cryoablation sits as a legal, FDA-cleared alternative for a small but very specific group of older women who want to avoid breast surgery and are willing to trade a scalpel for a carefully controlled blast of cold.
